Adverum Biotech 
Welcome,         Profile    Billing    Logout  
 3 Products   0 Diseases  3 Products   4 Trials   148 News 
10 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ADVM-043 / Adverum Biotech
ACTRN12624001290583: A phase 1 safety trial of CANN001, a hydrogel patch containing 2-deoxy-D-Ribose, in diabetic foot ulcers

Not yet recruiting
1
18
 
University of Western Australia, Cannenta
diabetic foot ulcer
 
 
ixoberogene soroparvovec (ADVM-022) / Adverum Biotech
ARTEMIS, NCT06856577: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Recruiting
3
284
US
Ixo-vec, Aflibercept
Adverum Biotechnologies, Inc.
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
03/30
03/30
INFINITY, NCT04418427: ADVM-022 Intravitreal Gene Therapy for DME

Completed
2
36
US
6E11 vg/eye of ADVM-022, AAV.7m8-aflibercept, 2E11 vg/eye of ADVM-022, Aflibercept, Eylea
Adverum Biotechnologies, Inc.
Diabetic Macular Edema, Diabetic Retinopathy
11/22
11/22
2022-002261-15: Study to Assess Safety and Efficacy of ADVM-022 in patients having already received Anti-VEGF Treatment for Neovascular (Wet) Age-related Macular Degeneration (nAMD)

Not yet recruiting
2
72
Europe
ADVM-022, Durezol, Suspension for injection, Intravitreal implant in applicator, Tablet, Eye drops, emulsion, OZURDEX, Prednisolon acis, Durezol
Adverum Biotechnologies, Inc., Adverum Biotechnologies, Inc.
Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD), Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD), Diseases [C] - Eye Diseases [C11]
 
 
LUNA, NCT05536973 / 2022-002261-15: Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration []

Active, not recruiting
2
69
Europe, US
ADVM-022
Adverum Biotechnologies, Inc., Parexel
Neovascular Age-related Macular Degeneration
08/24
08/28
OPTIC, NCT03748784: ADVM-022 Intravitreal Gene Therapy for Wet AMD

Completed
1
30
US
ADVM-022, AAV.7m8-aflibercept
Adverum Biotechnologies, Inc.
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
06/22
06/22
NCT04645212: Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Active, not recruiting
N/A
23
US
ADVM-022, AAV.7m8-aflibercept
Adverum Biotechnologies, Inc.
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
06/25
06/25
NCT05607810: Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

Active, not recruiting
N/A
22
US
ADVM-022, AAV.7m8-aflibercept
Adverum Biotechnologies, Inc.
Diabetic Macular Edema, Diabetic Retinopathy
04/26
04/26
LX2006 / Lexeo Therap
SUNRISE-FA, NCT05445323: Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

Active, not recruiting
1/2
8
US
Low dose LX2006, Mid Dose LX2006, High Dose LX2006
Lexeo Therapeutics
Friedreich Ataxia, Cardiomyopathy, Secondary
09/29
09/29
NCT05302271: Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

Recruiting
1
25
US
AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN, Prednisone
Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI)
Friedreich Ataxia, Cardiomyopathies, Cardiac Hypertrophy, Myocardial Fibrosis
12/28
12/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ADVM-043 / Adverum Biotech
ACTRN12624001290583: A phase 1 safety trial of CANN001, a hydrogel patch containing 2-deoxy-D-Ribose, in diabetic foot ulcers

Not yet recruiting
1
18
 
University of Western Australia, Cannenta
diabetic foot ulcer
 
 
ixoberogene soroparvovec (ADVM-022) / Adverum Biotech
ARTEMIS, NCT06856577: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Recruiting
3
284
US
Ixo-vec, Aflibercept
Adverum Biotechnologies, Inc.
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
03/30
03/30
INFINITY, NCT04418427: ADVM-022 Intravitreal Gene Therapy for DME

Completed
2
36
US
6E11 vg/eye of ADVM-022, AAV.7m8-aflibercept, 2E11 vg/eye of ADVM-022, Aflibercept, Eylea
Adverum Biotechnologies, Inc.
Diabetic Macular Edema, Diabetic Retinopathy
11/22
11/22
2022-002261-15: Study to Assess Safety and Efficacy of ADVM-022 in patients having already received Anti-VEGF Treatment for Neovascular (Wet) Age-related Macular Degeneration (nAMD)

Not yet recruiting
2
72
Europe
ADVM-022, Durezol, Suspension for injection, Intravitreal implant in applicator, Tablet, Eye drops, emulsion, OZURDEX, Prednisolon acis, Durezol
Adverum Biotechnologies, Inc., Adverum Biotechnologies, Inc.
Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD), Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD), Diseases [C] - Eye Diseases [C11]
 
 
LUNA, NCT05536973 / 2022-002261-15: Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration []

Active, not recruiting
2
69
Europe, US
ADVM-022
Adverum Biotechnologies, Inc., Parexel
Neovascular Age-related Macular Degeneration
08/24
08/28
OPTIC, NCT03748784: ADVM-022 Intravitreal Gene Therapy for Wet AMD

Completed
1
30
US
ADVM-022, AAV.7m8-aflibercept
Adverum Biotechnologies, Inc.
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
06/22
06/22
NCT04645212: Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Active, not recruiting
N/A
23
US
ADVM-022, AAV.7m8-aflibercept
Adverum Biotechnologies, Inc.
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
06/25
06/25
NCT05607810: Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

Active, not recruiting
N/A
22
US
ADVM-022, AAV.7m8-aflibercept
Adverum Biotechnologies, Inc.
Diabetic Macular Edema, Diabetic Retinopathy
04/26
04/26
LX2006 / Lexeo Therap
SUNRISE-FA, NCT05445323: Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

Active, not recruiting
1/2
8
US
Low dose LX2006, Mid Dose LX2006, High Dose LX2006
Lexeo Therapeutics
Friedreich Ataxia, Cardiomyopathy, Secondary
09/29
09/29
NCT05302271: Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

Recruiting
1
25
US
AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN, Prednisone
Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI)
Friedreich Ataxia, Cardiomyopathies, Cardiac Hypertrophy, Myocardial Fibrosis
12/28
12/29

Download Options